DAFTAR PUSTAKA

1. Levine DA, Santos JDL, Fleming G, Barakat RR, Markman M, Randall

ME. Handbook for Principles and Practice of Gynecologic Oncology.
Philadelphia: Lippincott Williams & Wilkins; 2010.p. 121-57.
2. Randall ME, Michael H, Long III H, Tedjarati S. Uterine Cervix.In:
Barakat RR, Markman M, Randall ME. Principles and Practice of
Gynecologic Oncology. 5th ed. Baltimore: Lippincott Williams & Wilkins;
2009:623-72.
3. Lindell K, Burri P, Studer HU, Altermatt HJ, Greiner RH, Gruber G.
Human Papilomavirus status in advanced cervical cancer: Predictive and
prognostic significance for curative radiation treatment. Int J Gynecol
Cancer 2005; 15: 278-84.
4. Franco EL, Franco ED, Ferency A. Cervical cancer : epidemiology,
prevention and the role of human papilloma virus.
CMAJ2001;164(7):1017-25.
5. Castellsague X. Natural history and epidemiology of HPV infection and
cervix. Gynecol Oncol 2008;110(Supplement 3):4-7.
6. Parkin DM. The global health burden of infection-associated caner in the
year 2002. Int J Cancer2006;118(12):3030-44.
7. Negi RR, Gupta M, Kumar M, et al. Concurrent chemoradiation in Locally
advanced carcinoma cervix patients. J Cancer Res Ther 2010;6: 159-66.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global Statistic, 2002. CA Cancer J
Clin 2005 Mar 1;55(2):74-108.
9. Munoz N, Fransceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al.
Role of parity ang human papilloma virus in cervical cancer: The IARC
multicentric case-control study. Lancet 2002; 359: 1093-1101.
10. Andrijono. Kanker Serviks. 3ed. Andrijono, editor. Jakarta: Pustaka Spirit;
2009: 59-125
11. Aziz MF. Gynecological Cancer in Indonesia, J Gynecol Oncol 2009;
20(1): 8-10.
12. Eggleston KS, Coker AL, Williams M. Cervical cancer survival by
socioeconomic status, race/ethnicity, and place of residence in Texas 1995-
2001. J Womens Health 2006; 15(8): 941-45.
13. Ferlay J. Bray F, Pisani P, Parkin D. Globocan 2002: Cancer Incidence,
Mortality and Prevalence Worldwide. IARC Cancer Base no.5. IARC
Press, Lyon: IARC Press 2004.
14. Kato S, Ohno T, Thephamongkhol K, et al. Multi-Institusional Phase II
Clinical Study of Concurrent Chemoradiotherapy for Locally Advanced
Cervical Cancer in East and Southeast Asia. Int. J. Radiat Oncol Biol Phys
2010;77:751-57
15. Aziz MF. Masalah kanker serviks. Cermin dunia kedokteran 2001;133:5-7.
16. Yayasan kanker Indonesia. Kanker di Indonesia tahun 2002 Data
Histopatologik. Jakarta: Direktorat Jenderal Pelayanan Medik Departemen

103
 Kesehatan RI. Badan Registrasi Kanker Perhimpunan Dokter Spesialis
Patologi Indonesia; 2002.
17. Parkin DM, Loui KS, Clifford G. Burden and Trends of Type-spesific
Human Papillomavirus Infections and Related disease in the Asia Pacifif
Region. ICI Monograph Series on HPV and cervical Cancer : Asia Pasific
Regional Report. USA: Elsivier; 2008.
18. Aziz MF. Faktor Kliniko-Patologik, Molekul Adhesi Sel E-Kadherin,
Katenin-A, dan Enzim Proteolitik Matriks Ekstraselular Kathepsin-D
sebagai Prediktor Metastasis Kelenjar Getah Bening dan Prognosis Kanker
Serviks Stadium awal. Jakarta: Program Studi Ilmu Kedokteran S3
Fakultas Kedokteran Universitas Indonesia; 2004.
19. Benedet JL, Pecorelli S, Ngan HYS, Hacker NF. Stagging Classification
and Clinical Practice Guidelines for Gynecologic Cancer. IGCS; 2006;3.
20. Hacker NF. Cervical Cancer. In : Bereck JS, Hacker NF, editors. Practical
Gynaecology Oncology. 4th ed. Philadelphia: Lippincott Williams &
Wilkins; 2005: 337-88.
21. Monk BJ, Tewari KS. Invasive Cervical Cancer. In: DiSaia PJ, Creasman
WT, editors. Clinical Oncology Gynecology. 7th ed. China: Elsevier;
2007:55-124.
22. Monk BJ. Chemotherapy for advanced and recurrent cervical carcinoma in
the new era of upfront chemotherapy and radiation: Have we arrived. The
Womens oncology review 2005; 5(2): 77-79.
23. Long III HJ, Lack NNI, Gostout BS. Prevention, Diagnosis, and Treatment
of Cervical Cancer. Mayo Clin Proc 2007; 82(12): 1566-74
24. Rose PG. Chemoradiation. Drug 2000; 60(6): 1566-74
25. Green JA, Kirwan JM, Tierna JF. Survival and recurrent after concomitant
chemotherapy and radiotherapy for cancer of uterine cervix: A Systemic
review and met-analysis. Lancet 2001; 2003(13): 580-86.
26. Vale C, Tierna JF, Steward LA, Collaboration CfCCM-A. Reducing
uncertainties about the effect of chemoradiotherapy for cervical cancer: A
systematic review and meta-analysis of individual patient data from 18
randomized trial. J Clin Oncol 2008; 26(35):5802-12.
27. Loizzi V, Cormio G, Loverro C, Selvaggi L, Disaia J, Capuccini F.
chemoradiation: Anew approach for the treatment of cervical cancer. Int J
Gynecol Cancer 2003; 13:580-86.
28. Niloff JM, Canistra SA. Cancer of the Uterine Cervix. The England
Journal of Medicine. April,1996;16;334: 1030-37.
29. Withney CW, Sause W, Bundi BN, et al. Randomized comparison of
fluoroucil plus cisplatin versus hidroxyurea as an adjuct to radiation
therapy in stage IIB-IVa carcinoma of the cervix with negative para-aortic
lymph node: A Gynecologic Oncologi Group and Southwest Oncology
Group study. J Clin oncol 1999;17:1339-48.

104
30. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent
chemotherapy compared with pelvic and para-aortic radiation for high-risk
cervical cancer. N Engl J Med 1999;340: 1137-43
31. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of the
major cancers in 1990. Int J Cancer 1999;80:827-41.
32. Toita T. Moromizato H, Ogawa K, et al. Concurrent chemoradiotherapy
using high-dose-rate intracavitary brachytherapy for uterine cervical
cancer, Gynecol Oncol 2005;96:665-700
33. Chen SW, Liang JA, Hung YC, et al. Concurrent weekly csiplatin plus
external beam radiotherapy and high-dose-rate barchytherapy for advanced
cervical cancer: A control cohort comparison with radiation alone on
treatment outcome and complication. Int J Radiat Oncol Biol Phys
2006;66:1370-77.
34. Lanciano R, Calkins A, Bundy BN, et al. Randomization comparision of
weekly cisplatin or protacted venous infusion of fluorouracil in
combination with pelvic radiation in advanced cervix cancer: A
Gynecologic Oncology Group study. J Clin Oncol 2005;23:8289-95.
35. Dewi R, Laila N. Free Disease Survival dan Respon Terapi Kemoradiasi
dibanding: Radiasi Pada Kanker Serviks Stadium Lanjut di RSUPN Cipto
Mangunkusumo Selang Waktu 1997-2004, Program Pendidikan Dokter
Spesialis Fakultas Kedokteran Universitas Indonesia. Jakarta ; 2006.
36. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al.
Natural Hystery of Cervical Human Papilloma Virus Infection in Young
Women: A longitudinal Cohort Study. Lancet 2001 Jun 9; 357(9271):
1831-36.
37. Franco EL, Franco ED, Ferency A. Cervical Cancer: Epidemiology,
prevention and the role of human papilloma virus. CMAJ 2001; 164(7):
1017-25.
38. Sanakaranarayanan R, Thara S, Esmy PO, Basu P. Cervical Cancer:
Screening and Therapeutic Perspectives. Med Princ Pract 2008; 17: 351-
64.
39. Basemen JG. The Epidemiology of Human Paplloma Virus Infection.
Journal Clin Virology 2005; 32: 16-24.
40. Villa LL. Biology of Genital Human Papilloma Viruses. Int J Gynaecol
Obstet 2006; 96: S3-7.
41. Saroyo YB, Sjamsudin S, Hardjolukito, Bachtiar A. Densitas
Mikrovaskular tumor sebagai Faktor Prediktor Respon Radioterapi pada
Kanker Sel Skuamosa Serviks. Majalah Obstetri Ginekologi Indonesia.
2000; 24; 109-16.
42. Winklestein W. Smoking and cervical cancer: Current status-A Review.
Am J Epidemiol 1990; 131: 945-57.
43. Hecyt SS. Etiology of Cancer: Tobacco. In : Devita VT, Lawrence TS,
Rosenberg SA. Cancer Principles & Practice of Oncology; Vol 2. 8th ed.
Philadelphia: Lippincott Williams & Wilkins; 2008:147-54.

105
44. Tolstrup J, Munk C, Thomson BL, et al. The Role of smooking and alcohol
intake in the development of high grade squamous intraepithelial lesion
among high risk HPV-positive women. Acta Obstet Gynecol Scand
2006;85(9): 1114-19.
45. Castelsague X, Diaz M, et al. Worldwide human papilloma virus etiology
of cervical adenocarcinoma and its cofactor: Implication for screening and
prevention. J Natl Cancer Inst 2006;98:303-15.
46. Vasilev SA, Schlaerth JB. Scalene lymph node sampling in cervical
carcinoma: A reappraisal. Gynecol Oncol 1990;37:120-24.
47. Staf Subbagian Onkologi Ginekologi. Penuntun Pelayanan-Pendidikan-
Penelitian. Bagian Obstetri Ginekologi. Jakarta;1998:80-83.
48. Kenter G. Early Cancer of The Cervix. In: Luesly DM, Barrasso R. Cancer
and Pre-Cancer of The Cervix. 1st ed. Philadelphia: Lippincott Williams &
Wilkins; 1998: 295-310.
49. Pocorelli S, Ngan HYS, Hacker NF. Stagging Classification and Clinical
Practice Guidelines for Gynecological Cancer,3rd ed. FIGA Comitte on
Gynecologic Oncology; 2006
50. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human
papillioma virus types in cytologically normal women in the International
Agency for Research on Cancer HPV prevalence surveys: A pooled
analysis Lancet 2005; 366(9490): 991-98
51. Wells M, Ostor AG, Crum CP, Franceschi, Tommasino M, Nesland JM et
al. WHO histological classification of tumors of the uterine cervix. In:
Tavassoli FA, Devilee P, editors. World Health Organization Classification
of Tumours. Pathology and Genetics Tumours of the Breast and Female
Genital Organs. Lyon France: IARC Press;2003:260.
52. Mutch DG. The new FIGO Stagging System for Cancers of The Vulva,
Cervix, Endometriu and Sarcomas. Gynecologic Oncology 2009; 115: 325-
28.
53. Devesa SS, Siverman DT, Young JL. Cancer Incidens and Mortality trends
among whites in United States 1947-84. Journal National Cancer
Institutions. 1987; 79; 701-70
54. Garcia AA. Cervical Cancer. MD, Medical Director of Clinical
Investigation Support Office, Assistant Professor, Departmen of Internal
Medicine, Division of Oncology. April 17, 2002.
55. Samsudin S. Manual prekanker dan kanker serviks uterus. Bagian obstetric
dan Ginekologi Fakultas Kedokteran Universitas Indonesia. Jakarta 1985.
56. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman
WT, et al. Carcinoma of Cervix Uteri.Int J Gynaecol Obstet 2006; 95: S1-
S256
57. Lai CH, Hsueh S, Hong J-H, Chang T-C, Tseng C-J, Chou H-H, et al. Are
Adenocarcinoma and Adenosquamous Carcinoma diffrent from Squamous
Carcinoma in stage IB and IIA Cervical Patients Undergoing Primary
Radical Surgery. Int J Gynecol Cancer 1999;9:28-36.

106
58. Susworo R. Radioterapi. Jakarta: Penerbit Universitas Indonesia; 2006:40-
51.
59. Perez CA, Barady LW, Halperin EC, Schmidt-Urlich RK. Principle and
Practice of Radiation Oncology. 3 ed. Philadelphia: Lippincot
Williams&Wilkins; 2000.
60. Yashar CM. Basic Principle in Gynecologic Radiotherapy. In: DiSaia PJ,
Creasman WT, editors. Clinical Gynecology Oncology. 7 ed. Philadelphia:
Mosbay; 2007:773-94.
61. Hill RP, Bristow RG. Molecular and Celullar Basis of Radiotherapy. In:
Tannock IF, Hill RP, Bristow RG, Harington L, editors. The Basic Science
of Oncology. 4 ed. Singapore: The McGraw-Hill Education (Asia);
2005:289-321.
62. Sohn D, Essman F, Schulze-Ostof K, Janicke RU. p21 Block Irradiation-
Induced Apoptosis Downstream of Mithochondria by Inhibition of Cyclin-
Dependent KInase-Mediated Caspase-9 Activation. Cancer Research
2006;66(23):11254-261.
63. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor
p21 in apoptosis. Mol Cancer Ther 2002 Jun;1(8):639-49.
64. Lammering G, Hewit T, et al. Epidermal growth factor receptor as genetic
therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst
2001; 93: 921-29.
65. Jhonson MT. Cancer of The Cervix. http://w.w.wmedical-library.org.
66. Leer JWH, Schueren EV. Prinsip-Prinsip Radioterapi. Dalam : Onkologi
Terjemahan Indonesia. Panitia Kanker RSUP DR Sardjito, Yogyakarta.
Edisi kelima revisi. 1996. 7: 201-15.
67. Bomford CK, Kunkler IH, Sherriff SB. Principles of Radiobiology. In:
Walter and Miller`s Textbook of Radiotherapy. Radiation Physics, Therapy
and Oncology. 5th ed. Churchill Livingstone. United Kingdom. 1993. 14:
253-63.
68. Wong LC, Ngan YS, Cheung NY, et al. Chemoradiation and Adjuvant
Chemotherapy in Cervical Cancer. J Clin Onco 1999; 17: 2055-9
69. Sastroasmoro S, Soehartati et al. Panduan Pelayanan Medis Departemen
Radioterapi RSUPN dr. Cipto Mangunkusumoa, Jakarta 2007:63-71
70. Virostek LJ, Kim RY, Spencer SA, Meredith RF, Jenelle RLS, Soong S-J,
et al. Postsurgical recurrent carcinoma: Reasessment and results of
radiation therapy options. Radiology 1996;201:559-63.
71. Singh et al. Histopathologic Parameters of Prognosis in Cervical Cancer-A
Review. Int J Gynecol Cancer. 2004; 14: 741-50.
72. Eisenhaver EA, Therasse P, Bogaerts J, et al. New respon evaluation
criteria in solid tumors: Revised RECIST guidelines (versi 1.1). European
Journal of Cancer 2009;45; 228-47

107
73. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting Result of
Cancer Treatment. Cancer 1981;47:207-14.
74. Southwest Oncology Group Clinical Research Manual. Response
Assesment. 2003 Jun.
75. Therasse P. Evaluation of response: new and standard criteria. Ann Oncol
2002;13-4:127-29.
76. Barillot I, Horiot JC, Pigneus J, et al. Carcinoma of the intact uterine
cervix treated with radiotherapy alone: A French cooperative study: update
and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol
Phys 1997;38:969-78.
77. Yaman C, Fridrik M. Three-dimensional ultrasound to assess the response
to treatment in gynecological malignancies. Gynecol Oncol 2005;97:665-
68.
78. Mayr NA, Yuh WTC, Taoka T, Wang JZ, Wu DH, Montebello JF, et al.
Serial therapy-induced changes in tumor shape in cervical cancer and their
impact on assessing tumor volume and treatment response. Am J
Roentgenol 2006;187:65-72.
79. Husband JE, Schwartz LH, Spencer J, et al. Evaluation of response to
treatment of solid tumors a consensus statement of the International
Cancer Imaging Society. Br J Cancer 2004;90:2256-60.
80. James K, Eisenhauer E, Christian M, et al. Measuring response in solid
tumors: unidimensional versus bidimensional measurement. J Natl Cancer
Inst 1999;91:523-28.
81. Mayr NA, Taoka T, Yuh WTC, Denning LM, Zhen WK, Paulino AC, et al.
Method and timing of tumor volume measurement for outcome prediction
in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol
Biol Phys 2002;52:14-22.
82. Mazumdar M, Smith A, Schwatz LH. A statistical simulation study finds
discordance between WHO criteria and RECIST guideline. J Clin
Epidemiol 2004;57:358-65.
83. Testa AC, Ludovisi M, Manfredi R, et al. Transvaginal ultrasonography
and magnetic resonance imaging for assessment of presence, size and
extent of invasive cervical cancer 2009;34:335-44.
84. Hricak H, Gatsonis C, Chi DS, Amendalo MA, et al. American College of
Radiology Imaging Network 6651; Gynecologic Oncology Group 183,
Role of imaging in pretreatment evaluation of early invasive cervical
cancer: results of the intergroups study American College of Radiology
Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol
2005;36: 9329-37.
85. Ferradina G, Legge F, Fagotti A, Fanfani F, Distefano M, Morganti A,
Cellini N, Scambia G. Preopreative concomitant chemoradiotherapy in
locally advanced cervical cancer: safety, outcome,and prognostic
measures, Gynecol Oncol 2007; 107: S127-32.

108
86. Ghi T, Giunci S, Kuleva M, Santini D, Savelli L, Formelli G, Casadio P,
Costa S, Meriggiola MC, Pelusi G. Three-dimentional transvaginal
sonography in local staging of cervical carcinoma: description of a novel
technique and preliminary results. Ultrasound Obstet Gynecol
2007;30:778-82.
87. Fischerova D, Cibula D, Stenhova H, Vondrichova H, Calda P, Zikan M,
Freitag P, Slama J, Dundr P, Balacek J. Transrectal ultrasound and
magnetic resonance imaging in staging of early cervical cancer. Int J
Gynecol Cancer 2008;18:766-72.
88. Eifel PJ. Radiation therapy. In: Berek JS, Hacker NF. Practical
Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams &
Wilkins; 2005:119-54.
89. RTOG-Acute Radiation Morbidity Scoring Criteria.
File://G:\Radiotherapy\Side effects\RTOG-Acute Radiation Morbidity.htm
90. Yayasan Kanker Indonesia. Kanker di Indonesia tahun 2002 Data
Histopatologik. Jakarta : Direktorat Jendral Pelayanan Medik Departemen
Kesehatan RI. Badan Registrasi Kanker Perhimpunan Dokter Spesialis
Patologi Indonesia 2002.
91. Maxwell GL, Berchuck A. Biology and Genetics. In: Practical Gynecology
Oncology. 3rd Ed. Berek and Hacker, Lippincott Williams and Wilkins.
USA. 2000. 1; 3-38.
92. Parkin DM, Loui KS, Clifford G. Burden and Trends of Type-spesific
Human Papillomavirus Infections and Related disease in the Asia Pacifif
Region. ICI Monograph Series on HPV and cervical Cancer : Asia Pasific
Regional Report. USA: Elsivier; 2008.
93. R Attanoos et al. Primary Adenocarcinoma of the Cervix. A
Clinicopathologic study of prong ostic variables in 55 cases. Int J Gynecol
Cancer 1995; 5: 179-186.
94. Kaneyasu Y, Okawa MK, Okawa T. Clinical evaluation of
Chemoradiotherapy for Advanced Cervical Cancer. Gan To Kagaku
Ryoho. 1997; 24-14:2084-2091.
95. Campion M. Preinvasive Disease. In: Practical Gynecology Oncology. 3 rd
Ed. Berek and Hacker, Lippincott Williams and Wilkins. USA. 2000. 8;
271-344.
96. Aziz FM. Kemoterapi pada Kanker Serviks. Majalah Obstetri Ginekologi
Indonesia 1996;20-3: 186-192.
97. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW.
Sublethal irradiation of human tumor cells modulates phenotype resulting
in enhanced killing by cytotoxic T lymphocytes. Cancer Res
2004;64:7985-7994.
98. Wright TC. Pathology of HPV Infection at The Cytologic and Histologic
Levals: Basis for a 2-tired Morphologic Classification System. Int J
Gynaecol Obstet 2006; 94: S22-31.

109
99. Saleh AG. Kemoterapi. Dalam: Aziz MF, Andrijono, Saifuddin AB. Buku
Acuan Nasional Onkologi Ginekologi. Edisi Pertama. Jakarta: Yayasan
Bina Pustaka Sarwono Prawirohardjo; 2006:369-74.
100. Markman M. Chemotherapy. In: Berek JS, Hacker NF. Practical
Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams &
Wilkins; 2005.p. 89-116.
101. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden E.T.,
Carbone, P.P.: Toxicity And Response Criteria Of The Eastern
Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55
102. Ohara K, Tanaka YO, Tsunoda H, Oki A, Satoh T, Onishi K, et al.
Preliminary estimation of treatment effect on uterine cervical squamous
cell carcinoma in terms of tumor regression rate. Rad Med 2005;23:25-29.
103. Cornain S, Rashid R, Nazar IM, Yusuf A, Asikin N, Sudarsona CS, et al.
Program Kerjasama Penelitian dan registrasi Kanker. Makalah Rapat Kerja
Nasional YKI.1992.
104. Laila N, Chaterine, et,al. Distribution of Age, Stage, and Histopathology of
Cervical Cancer: A Retrospective study on Patients at Dr. Cipto
Mangunkusumo Hospital Jakarta, Indonesia, 2006-2010. Indones J Obstet
Gynecol 2011;35-1:21-24.
105. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets -
Cancer of Cervix Uteri.1999 (http://seer.cancer.gov/statfacts/html/
cervix.html.) Ref Type: Online Source
106. Kundu S, Basu S, Acharya S, Dastidar AG, Roy A. Chemoradiation in
locally advanced cervical cancer: A Randomized Trial. Indian Journal of
Medical & Paediatric Oncology 2008; 29(4):12-7.
107. Choi CY, Ng WT, Chang ATY, Soong IS, Lee AWM. Analysis of cervical
cancer in Chinese patients treated with chemoradiation or radiotherapy
alone. J HK Coll Radiol 2007;10:51-8
108. Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. Comparison of
chemoradiation as postoperative adjuvant therapy in cervical cancer
patients with intermediate-risk factors. Eur J Surg Oncol 2008;10:1-5.
109. Chufal KS, Chufal, Madhup Rastogi, Srivastava M, Pant MC, Bhatt MLB,
Srivastava K. Concurrent chemoradiotherapy for locally advanced cervical
cancer using Gemcitabine: non-randomized comparison of three sequential
protocols. Cancer Therapy 2007;5:43-54.
110. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe D, Maiman MA,
Pearson DLC, Insalaco S. Concurrent cisplatin-based radiotherapy and
chemotherapy for locally advanced cervical cancer. N Engl J Med
1999;340:1144-53.
111. Cott M, Path FRCP. The Pathology of Cervical Cancers. In: Ayhan A,
Gultekin M, Dursun P. Text Book of Gynaecological Oncology. Gunes
Publishing. Ankara. 2010.95: 434-8.

110
112. Sakata K, Sakurai H, Suzuji Y, Kato S. Ohno T, Tita T, Kataoka M, Eiichi
T, Kaneyasu Y, Uno T, Harima Y, Nakano T. Result of concomitant
chemoradiation for cervical cancer using high dose rate intracavitary
brachytherapy: Study of JRSOG (Japan Radiation Oncology Study Group).
Acta Oncologica 2008;47: 434-41.
113. Kanti AR, Ranjan DA, Snehamay C, Kumar BP, Diptimoy D, Srijit G.
Concomitant chemoradiation in locally advanced carcinoma of cervix. J
Obstet Gynecal India 2007;57:145-50.
114. Kosary CL. Figo state, histology, histologic grade, and and race as
prognostic in determining survival for cancer of the female gynecological
system: an analysis of 1997-1998 SEER case for cancer of cancer of the
endometrium, cervix, ovary, vulva and vagina. Semin Surg Oncol
1994;10:31-46.
115. Bhavaraju VMK, Reed NS, Habeshaw T. Acute toxicity of concomitant
treatment of chemoradiation with single agent cisplatin in patients with
carcinoma of the cervix. Thai J of Physiol Sciences 2004;17:90-7.
116. Saibishkumar EP, Patel FD, Sharma SC. Result of a phase II trial of
concurrent chemoradiation in the treatment of locally advanced carcinoma
of uterine cervix: An experience from India. Bull Cancer 2005;92:E7-12
117. Tan LT, Russel S, Burgess L. Acute toxicity of Chemo-radiation for
cervical cancer: The Addenbrookes Experience. Clin Oncol 2004;16:255-
260
118. Walker JL, Morrison A, DiSilvestro P, Gruenigen VE. A phase I/II study
of extended field radiation therapy with concomitant paclitaxel and
cisplatin chemotherapy in patients with cervical carcinoma metastatic to
the para-aortic lymph nodes: A gynecologic oncology group study.
Gynecol Oncol 2009;112:78-84.
119. National Cancer Institute Clinical Announcement. Concurrent
chemoradiation for cervical cancer. February, 1999.
(http://www.cancer.gov/newscenter/cervicalcancer).
120. Pearcy R, Brundage M, Drouin P, et al: Phase III trial comparing radical
radiotherapy with and without cisplatin chemotherapy in patients with
advanced squamous cell cancer of cervix. J Clin Oncol 2002;20:966-72.
121. Nag S, Chao C, Erickson B, et al. For the American Brachytherapy for
carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002:52:33-48

111